Novo to Help Develop Long-Acting Basal Insulin

Feb 1, 2000

Flamel Technologies and Novo Nordisk announced that they will collaborate on developing Basulin, a long-acting, once-a-day formulation of human insulin that can be used by people with type 1 and 2 diabetes.

According to a Flamel Technologies press release, the terms of the agreement specify that Novo will have exclusive worldwide development and marketing rights to Basulin, while Flamel receives up-front licensing fees of $5 million, including $1 million received in early December 1999, as well as $37 million in milestone payments and royalties of future product sales. Novo will subsidize all clinical trials and ?product development of Basulin.

"As a leading provider of insulin products for the treatment of diabetes, Novo Nordisk is the ideal development and marketing partner for Basulin," says Gerard Soula, president and CEO of Flamel.

In preclinical tests, Basulin provided continuous, 24-hour coverage compared to standard 12-hour coverage provided by currently marketed products. A phase 1 clinical trial using Basulin is underway in the United Kingdom and results are expected early this year.

Click Here To View Or Post Comments

Categories: Diabetes, Insulin, Novo Nordisk, Type 1 Issues


Take the Diabetes Health Pump Survey
See What's Inside
Read this FREE issue now
For healthcare professionals only
  • What's on the Horizon with Diabetes Research and Therapy
See the entire table of contents here!

You can view the current or previous issues of Diabetes Health online, in their entirety, anytime you want.
Click Here To View

See if you qualify for our free healthcare professional magazines. Click here to start your application for Pre-Diabetes Health, Diabetes Health Pharmacist and Diabetes Health Professional.

Learn More About the Professional Subscription

Free Diabetes Health e-Newsletter

Latest
Popular
Top Rated
Print | Email | Share | Comments (0)

You May Also Be Interested In...


Comments


Add your comments about this article below. You can add comments as a registered user or anonymously. If you choose to post anonymously your comments will be sent to our moderator for approval before they appear on this page. If you choose to post as a registered user your comments will appear instantly.

When voicing your views via the comment feature, please respect the Diabetes Health community by refraining from comments that could be considered offensive to other people. Diabetes Health reserves the right to remove comments when necessary to maintain the cordial voice of the diabetes community.

For your privacy and protection, we ask that you do not include personal details such as address or telephone number in any comments posted.

Don't have your Diabetes Health Username? Register now and add your comments to all our content.

Have Your Say...


Username: Password:
Comment:
©1991-2014 Diabetes Health | Home | Privacy | Press | Advertising | Help | Contact Us | Donate | Sitemap

Diabetes Health Medical Disclaimer

The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. All content, including text, graphics, images, and information, contained on or available through this website is for general information purposes only. Opinions expressed here are the opinions of writers, contributors, and commentators, and are not necessarily those of Diabetes Health. Never disregard professional medical advice or delay seeking medical treatment because of something you have read on or accessed through this website.